Azure

Azure Biotech is a private, clinical-stage biotechnology company focused on developing innovative therapies for women's health, particularly postmenopausal conditions. The company's lead therapeutic candidate, AZU-101, is a topical formulation of lasofoxifene, a selective estrogen receptor modulator (SERM) licensed from Ligand Pharmaceuticals. AZU-101 is being developed as a non-estrogen treatment for vulvovaginal atrophy (VVA), also known as genitourinary syndrome of menopause (GSM), offering a potential solution for breast cancer survivors who are often restricted from using estrogen-based therapies. In addition to its drug development efforts, Azure Biotech operates an in vitro diagnostics (IVD) division that manufactures and distributes a variety of rapid diagnostic tests and point-of-care platforms globally.